These data are in line with a study by Kang et al. [106], demonstrating, in a population of Chinese patients with systolic HF (SHF), that GRK5 Leu41polymorphism reduced the risk of SHF morbidity after β-blocker therapy, compared to the Gln41 variant. This evidence concerns the gene GRK5 and hydrops fetalis.